Split ruling reinstates DOJ subpoena to gender‑affirming care provider, finding the administration may pursue investigations consistent with its policy agenda.
FD&C Act 1938
FDA issues multiple July 7 warnings over unauthorized ketamine products
Quick Read
Premium
A series of FDA warning letters flagged several injectable keratin hair‑straightening products for lacking required authorization.
Both stakeholders say that AI should support clinical workflows and that clinicians should maintain decision-making authority.
According to the regulator, ExThera Medical sent its Seraph 100 blood filters to a hospital for emergency/compassionate use without first obtaining permission.
The federal regulator contends the four biologics firms lack appropriate testing and marketing authorization.
According to new guidance, certain devices and software that track metrics such as heart rate and activity level will require less rigorous pre-market reviewal.
The three letters point to an enforcement posture toward manufacturers marketing biologics derived from human placentas and umbilical cords.
Key considerations for medical device manufacturers and how to prepare for a cybersecurity incident.